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Neonatal hypoxic-ischemic encephalopathy (HIE) occurs in 3-5 newborns per 1,000 live births. 1 Historically, HIE resulted in significant morbidity and mortality 2 ; however, in recent years, therapeutic hypothermia (TH) has emerged as the standard of care, leading to reductions in death or major neurodevelopmental disability. [3] [4] [5] [6] [7] [8] [9] In addition, TH may reduce seizures in neonates with moderate HIE. 10 Despite these improvements, the incidence of acute symptomatic seizures remains high, and many neonates experience a high seizure burden. 11, 12 Neonates treated with TH for HIE most commonly experience seizures on the initial 1-2 days of TH and during rewarming on day 4. 12, 13 Despite the high incidence of acute symptomatic seizures, the risk of future epilepsy in this population may be low. 5 In addition, there is growing concern about the sedating and potentially neurotoxic effects of antiseizure medications (ASMs), particularly phenobarbital. [14] [15] [16] [17] For these reasons, at some institutions, care has evolved toward ASM discontinuation prior to hospital discharge. 18 However, the impact of this practice on future seizures is unknown. Among neonates treated with TH for HIE, we aimed to determine the risk of seizure occurrence after hospital discharge and whether shorter ASM treatment duration was associated with this outcome.
Patients and Methods
The Children's Hospital of Philadelphia (CHOP) Institutional Review Board approved this study. We performed a single-center, retrospective study of consecutive neonates treated with TH for HIE from June 2010 through December 2014. All neonates treated with TH for HIE during this period were included. Subjects were identified using a database maintained by the neonatal intensive care unit (NICU) that catalogs clinical data, including medications at discharge. Based on our institutional pathway, TH was initiated within 6 h of birth. All neonates underwent continuous electroencephalography (cEEG) monitoring during TH and through rewarming, or for 24-48 h after the cessation of the last seizure. Magnetic resonance imaging (MRI) scans were performed within 24-48 h of rewarming in nearly all neonates, except when neonates were not medically stable for transport to MRI at that time. All neonates ultimately had MRI scans, except for those neonates who died prior to discharge. EEG monitoring was performed using Grass-Telefactor video-EEG equipment and a standard neonatal 10-10 electrode montage. All EEG data were interpreted by trained pediatric electroencephalographers. Clinical management was performed by the neonatal and neonatal neurology consultation services. There was no institutional pathway determining whether neonates continue ASMs after discharge; therefore, the decision to discontinue ASMs was made by the clinical team on an individual basis using patient characteristics such as seizure burden, responsiveness of seizures to ASM treatment, and severity of injury on MRI. Data regarding cEEG and MRI findings were obtained by reviewing reports in the electronic medical record. The occurrence of clinical or electrographic seizures during follow-up was determined by reviewing clinical care notes and EEG reports from routine follow-up appointments with neurology and from structured follow-up appointments with the neonatal follow-up clinic at 3, 6, 12, 18, and 24 months, and additionally as needed.
Clinical variables were defined as follows. HIE severity was determined prior to TH initiation by the admitting neonatologist using a structured clinical examination to assess the degree of encephalopathy. Initial EEG background was classified as the following: (1) 19 Electrographic seizure exposure during admission was classified as the following: (1) rare if there were 1-2 seizures, (2) occasional if there were 3-10 seizures, (3) frequent if there were >10 seizures, or (4) status epilepticus if individual seizures lasted >5 min or if 50% of any 1 h epoch contained electrographic seizure. MRI reports were reviewed by one clinician (MPF) blinded to clinical and EEG data on two occasions spaced >1 month apart. MRI injury distribution was scored using published methods, modified to include diffusion-weighted imaging (DWI) signal abnormality in addition to abnormalities on T 1 -and T 2 -weighted images. 20 MRI images were reviewed when the reports were not sufficiently clear for scoring. Time to ASM discontinuation was measured from the date of NICU discharge to the date of ASM discontinuation.
Data were summarized by standard descriptive statistics, including median/interquartile range (IQR) or mean/standard deviation (SD) for continuous variables, or as percentages for categorical variables. Comparisons between outcome groups were made using Fisher's exact test for categorical exposure variables and Kruskal-Wallis test for continuous exposure variables with nonparametric distributions. A Kaplan-Meier survivor function curve was generated to illustrate time to seizure recurrence. Further analysis of the influence of exposure variables on survivor function was curtailed due to a small number of outcome events.
Results
Eighty-one neonates underwent TH for HIE during the study period. Nine neonates (11%) died prior to discharge as a result of withdrawal of technological support, and 13 neonates (18%) were lost to follow-up, yielding 59 neonates (73%) in the remaining cohort (Fig. 1) . Table 1 that the cohort with follow-up data is representative of the full cohort. Acute symptomatic seizures occurred in 35 (59%) of 59 neonates. These included 21 neonates (36%) with electrographic seizures identified by cEEG during or after TH, and 14 neonates (24%) with clinical seizures that were treated without subsequent electrographic seizures on cEEG. ASMs were continued on discharge for 17 (49%) of 35 neonates with acute symptomatic seizures, including 15 neonates with electrographic seizures identified by cEEG and two neonates with clinically apparent seizures prior to cEEG initiation. The majority of the seizures in the neonatal period were subclinical. Those with clinical signs were classified as focal with impaired awareness, often with lip smacking and eyelid fluttering, focal tonic with stiffening of extremities, or focal clonic.
The median follow-up time was 19 months (IQR 11-25). Four neonates experienced seizures during the follow-up period, all of whom had acute symptomatic seizures. Four neonates represent 7% of the 59 neonates with available follow-up data and 11% of the 35 neonates with acute symptomatic seizures. All four neonates were discharged from the hospital on an ASM. None of these neonates had ongoing seizures at the time of discharge. The first unprovoked seizure in these patients occurred at ages 4, 15, 16, and 48 months (Fig. 2) . The infants with seizure occurrence at 4, 15, and 16 months were on standard ASM doses at the time, whereas the child with seizures at 48 months had discontinued ASM several years prior. These four patients were diagnosed with epilepsy because they had two or more unprovoked seizures in follow-up. Their epilepsy was classified as focal with impaired awareness, with hemiclonic or dyscognitive seizures. One patient developed infantile spasms. None of the neonates with acute symptomatic seizures who discontinued ASM prior to discharge experienced seizures during the follow-up period. In addition, all neonates who were seizure-free during the acute period remained seizure-free during the follow-up period.
The characteristics that distinguished neonates who experienced seizures during the follow-up period from those who did not included lower cord gas pH (6.69 AE 0.11 vs. 7.00 AE 0.20, p = 0.02), longer median admission length (34 days [IQR 27-50] vs. 18 days [IQR [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , p = 0.02), and higher likelihood of discharge from the hospital on an ASM (100% vs. 42%, p = 0.05, see Table 1 ). The presence of MRI injury was associated with a higher risk of seizures during the follow-up period, but the difference was not statistically significant (75% vs. 57%; p = 0.08). Table 2 summarizes the clinical characteristics of neonates who experienced seizures during the follow-up period. Because of the low prevalence of seizure occurrence in follow-up, a multivariate predictive model for seizure occurrence could not be constructed.
Characteristics that distinguished neonates who continued ASM after discharge from those who did not included longer median admission length (27 days [16, 32] vs. 18 days [11, 23] , p = 0.02), higher likelihood of having electrographic seizures (88% vs. 33%, p < 0.01), and lower likelihood of having a normal brain MRI (19% vs. 61%, p = 0.03, see Table 1 ).
Discussion
This study evaluated the risk of seizure occurrence after hospital discharge in neonates with HIE treated with TH, with attention to whether ASM discontinuation prior to discharge impacted the risk of seizures during the follow-up period. There are clinically meaningful findings. First, the risk of seizure occurrence after discharge in this population is low. Seizures occurred in follow-up in only 7% of neonates with available follow-up data (including neonates Figure 1 . Study design. Eighty-one neonates were eligible and 59 had follow-up data available. Thirty-five neonates experienced acute symptomatic seizures, whereas 24 did not. Of those with acute symptomatic seizures, four had seizures in followup. Of those without acute symptomatic seizures, none had seizures in follow-up. Epilepsia ILAE who did and did not experience acute symptomatic seizures) and 11% of neonates with acute symptomatic seizures. This is consistent with the Whole Body Hypothermia for the Treatment of Perinatal Asphyxial Encephalopathy (TOBY) trial for TH, in which 10% of subjects required ASMs for treatment of epilepsy at 18 months of age. 5 Second, infants for whom ASMs were discontinued prior to hospital discharge did not have an increased risk of seizure occurrence during the follow-up period.
Determining how long to treat a neonate after resolution of acute symptomatic seizures with an ASM is an important clinical question. Phenobarbital, the most frequently administered ASM, may negatively impact brain development, and it can induce neuronal apoptosis in animal models even after a single dose. [15] [16] [17] Studies of human children exposed in utero to ASM have also demonstrated an increased risk of cognitive impairments in later childhood. [21] [22] [23] [24] In addition, phenobarbital has been associated with lower intelligence quotient and lasting cognitive impairments in children who were treated for prevention of febrile seizures. 14,25 Given these concerns, ASM should be used judiciously in neonates already at risk for neurodevelopmental impairments due to HIE. Thus if effective control of acute symptomatic seizures can be obtained with limited ASM exposure and without an increased risk of future seizures, then it is important to precisely define the optimal duration of ASM treatment. This study represents an initial step toward this goal, and it provides evidence that ASM can be discontinued for many neonates prior to hospital discharge. This study has several strengths. First, this cohort is one of the largest outside of the pivotal clinical trials of TH for HIE. Second, these data are generalizable to other neonatal referral centers, since they are derived from consecutively treated neonates. Further, key data are consistent with those of prior reports related to acute symptomatic seizures, including a 36% incidence of electrographic seizures. [10] [11] [12] [13] [26] [27] [28] Notably, the cohort contains neonates who experienced clinical seizures but who did not have electrographic seizures on cEEG. Despite the fact that neonatal seizures are prone to misidentification, 29 we included these neonates because clinical seizures are an indication for initiating TH, and a cohort including them reflects the patient population typically encountered by practicing neonatologists and pediatric neurologists. Third, relatively few patients were lost to follow-up, which improves our confidence in the conclusion that the risk of seizure occurrence in the initial 2 years after hospital discharge is indeed low. The study has several limitations. First, because of its retrospective design, some of the clinical variables cannot be defined optimally. For example, seizure exposure measurement is restricted to the number of seizures present on cEEG, which is not the most accurate measure of seizure exposure. Other studies have quantified seizure exposure in terms of the time spent experiencing electrographic seizures, 10, 13, 26, 27, 30 or have calculated a seizure score that encompasses multiple parameters. 11 The most precise manner of quantifying seizure exposure is not clear; however, the optimal measure would likely need to account for both time spent seizing and the area of cortex involved. These considerations will be important in the design of future prospective studies. Second, despite our large cohort, the limited number of neonates experiencing future seizures prohibits multivariate analysis to identify risk factors for seizure occurrence. Our study did identify some potentially important commonalities among those patients who experienced seizures after discharge, including low cord gas pH, prolonged hospitalization, and the presence of injury on MRI scan. In addition, neonates discharged on an ASMs were more likely to have a prolonged hospital admission, electrographic seizures on cEEG, and abnormal brain MRI results. These findings likely reflect an increased clinical concern about the risk of future seizures in these neonates; however, the extent these parameters predict seizure recurrence remains unclear. Third, although our median followup interval of 19 months may not be sufficient capture the entire period of risk for developing epilepsy, no study has reported on long-term risk for seizure occurrence after TH for HIE. A larger, multicenter, prospective study is needed to better evaluate risk factors for later epilepsy over the longer term, with the aim of providing guidance to clinicians deciding whether to prescribe an ASM upon discharge. However, if a lengthy period exists in which ASMs are not needed, avoiding unnecessary ASM exposure could still have neurodevelopmental benefits even if seizures recur later.
Conclusion
Most neonates managed with TH for HIE who experience acute symptomatic seizures do not have additional seizures in the 1.5 years after hospital discharge. Moreover, discontinuation of ASMs prior to discharge is not associated with an increased risk of seizure occurrence later. Thus many neonates treated with ASMs for acute symptomatic seizures can have the drugs discontinued prior to discharge. This may be particularly applicable for neonates with few seizures that are easily controlled with ASMs, if the EEG appears only mildly abnormal, or if the brain MRI does not show severe injury. Priorities for further research include elucidating which neonates with HIE are at the highest risk of seizures later in life, and whether more prolonged ASM administration after the period of acute illness may be indicated in a specific cohort.
